Initiation of Acid Suppression Therapy Prospective Outcomes for Laryngomalacia
A legfontosabb adatok
- Ki végzi
- Reema Padia
- Hol
- Pittsburgh (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Leállítva
- Fázis
- 1/2. fázis
- Résztvevők
- 65 fő vett részt
- Kezdés
- 2020. nov. 18.
- Befejezés
- 2024. máj. 17.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Famotidine
- Speech Language Therapy
- A regiszteradat frissítve
- 2025. július 20.
- Miért állt le
- Slow recruitment due to few eligible patients
Ki vehet részt
- Életkor
- 0 hónap – 6 hónap
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 14 feltétel megnézéseKevesebb
Ki vehet részt
- Pediatric patients ages 0 to 6 months who do need meet the criteria at the initial appointment for supraglottoplasty
- Seen in University of Pittsburgh Medical Center (UPMC) Children's Hospital of Pittsburgh (CHP) Otolaryngology Department
- Laryngomalacia without prolonged (>20 seconds) cyanosis, apnea, nor failure to thrive
Ki nem vehet részt
- Patients with symptoms that necessitate surgery
- Patients with a prior cardiac surgery
- Patients with lung disease
- Laryngomalacia with prolonged (>20 seconds) cyanosis, apnea, and failure to thrive
- Patients with a syndrome
- Patients with AST prescribed prior to the initial otolaryngology consult
- Children over the age of 6 months old will be excluded from participation
- Premature infants (<37 weeks gestation)
- Sleep induced laryngomalacia
- Patients with craniofacial abnormalities
- Patients with additional airway abnormalities, seen before or at consult
Helyszínek itt: Egyesült Államok
- UPMC Children's Hospital of PittsburghPittsburgh, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
Laryngomalacia (LM) is the most common cause of stridor in infants. Symptoms of gastroesophageal reflux (GER) are often seen in the setting of LM; therefore, acid suppression therapy (AST) has been empirically used in the management of this disorder. The investigators recently performed a retrospective chart review assessing improvement of airway and dysphagia symptoms, weight gain, and need for surgery with AST. It was found that there was a similar improvement between LM severity groups and most patients received AST (96.6%). It is unclear if these improvements are due to AST or natural resolution of the disease. With heightened concerns of side effects related to AST in infants, particularly among those born prematurely, judicious use of these medications is needed. The investigators are now performing a prospective study looking at the outcome differences in patients with laryngomalacia who are evaluated by speech language therapy (SLP) alone versus those with SLP evaluation and acid suppression therapy (famotidine).
A vizsgálat 2 csoportja
- Speech Language Therapy AloneA vizsgált kezelés
Patients in this group will receive a routine swallowing evaluation by a speech language pathologist. Patient caregivers will fill out the Infant Gastroesophageal Reflux Questionnaire (I-GERQ-R) and the Pittsburgh Airway Symptom Score (PASS) the day of the appointment and at the 3-month follow up appointment.
Kezelés: Speech Language Therapy
- Speech Language Therapy and Acid Suppression TherapyMár használt kezelés, összehasonlításként
Patients in this group will receive a routine swallowing evaluation by a speech language pathologist and famotidine (acid suppression therapy). Patient caregivers will fill out the Infant Gastroesophageal Reflux Questionnaire (I-GERQ-R) and the Pittsburgh Airway Symptom Score (PASS) the day of the appointment and at the 3-month follow up appointment.
Kezelés: Famotidine és Speech Language Therapy
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Publikációk
- A regiszteradat frissítve
- 2025. július 20.